Zydus Lifesciences Reports Four Observations from USFDA Inspection at LiqMeds, U.K.
1 report, 1 independent
Updated Sat 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Zydus Lifesciences disclosed that the U.S. health regulator concluded its inspection at LiqMeds, U.K., between November 9 and 13, resulting in four observations. The company stated it will work closely with the U.S. Food and Drug Administration to address these observations quickly. LiqMeds Group was acquired by Zydus Lifesciences via Zydus Pharmaceuticals U.K. in October 2023.
From thehindu.com
Why it matters
The inspection findings relate to the operations of LiqMeds, U.K., following its acquisition by Zydus Lifesciences. The need to address regulatory observations could potentially affect the company's ongoing production or market access.
From thehindu.com